Chalkley Microvessel but not Lymphatic Vessel Density Correlates with Axillary Lymph Node Metastasis in Primary Breast Cancers

  • Published : 2013.01.31


This study aimed to investigate tumor microvessel density (MVD) and lymphatic vessel density (LVD) using the Chalkley method as predictive markers for the risk of axillary lymph node metastasis and their relationship to other clinicopathological parameters in primary breast cancer cases. Forty two node-positive and eighty node-negative breast cancers were immunostained for CD34 and D2-40. MVD and LVD were counted by the Chalkley method at x400 magnification. There was a positive significant correlation of the MVD with the tumor size, coexisting ductal carcinoma in situ (DCIS) and lymph node metastases (P<0.05). In multivariate analysis, the MVD (2.86-4: OR 5.87 95%CI 1.05-32; >4: OR 20.03 95%CI 3.47-115.55), lymphovascular invasion (OR 3.46, 95% CI 1.13-10.58), and associated DCIS (OR 3.1, 95%CI 1.04-9.23) independently predicted axillary lymph node metastasis. There was no significant relationship between LVD and axillary lymph node metastasis. However, D2-40 was a good lymphatic vessel marker to enhance the detection of lymphatic invasion compared to H and E staining. In conclusion, MVD by the Chalkley method, lymphovascular invasion and associated DCIS can be additional predictive factors for axillary lymph node metastases in breast cancer. No relationship was identified between LVD and clinicopathological variables, including axillary lymph node metastasis.


  1. Timar J, Csuka O, Orosz Z, Jeney A, Kopper L (2002). Molecular pathology of tumor metastasis II. Molecular staging and differential diagnosis. Pathol Oncol Res, 8, 204-19.
  2. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004). Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res, 64, 2941-55.
  3. Vleugel MM, Bos R, van der Groep P, et al (2004). Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol, 57, 746-51.
  4. Vermeulen PB, Gasparini G, Fox SB, et al (1996). Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer, 32, 2474-84.
  5. Weidner N, Semple JP, Welsh WR, Folkman J (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med, 324, 1-8.
  6. Weidner N, Folkman J, Pozza F, et al (1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst, 84, 1875-87.
  7. Faoro L, Hutto JY, Salgia R, et al (2008). Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Arch Pathol Lab Med, 132, 1882-8.
  8. Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, 15-8.
  9. Guidi AJ, Berry DA, Broadwater G, et al (2000). Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Ints, 92, 486-92.
  10. Hansen S, Sorensen FB, Vach W, et al (2004). Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients. Histopathol, 44, 428-36.
  11. Lee SH, Lee SJ, Jin SM, et al (2012). Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid carcinoma. Clin Exp Otorhinolaryngol, 5, 150-5.
  12. Mandriota SJ, Jussila L, Jeltsch M, et al (2001). Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J, 20, 672-82.
  13. Munoz-Guerra MF, Marazuela EG, Martin-Villar E, Quintanilla M, Gamallo C (2004). Prognostic significance of intratumoral lymphangiogenesis in squamous cell carcinoma of the oral cavity. Cancer, 100, 553-60.
  14. Offersen BV, Borre M, Overgaard J (2003). Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer, 39, 881-90.
  15. Pepper MS (2001). Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res, 7, 462-8.
  16. Saad RS, Kordunsky L, Liu YL, et al (2006). Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol, 19, 1317-23.
  17. Skobe M, Hawighorst T, Jackson DG, et al (2001). Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med, 7, 151-2.
  18. Sullivan CA, Ghosh S, Ocal IT, et al (2009). Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer. Hum Pathol, 40, 156-65.
  19. Attasara P, Buasom R (2009). Hospital-based cancer registry 2008. Bangkok: National Cancer Institute.
  20. Bast RC Jr, Ravdin P, Hayes DF, et al (2001). 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American society of the clinical oncology. J Clin Oncol, 19, 1865-78.
  21. Beasley NJ, Prevo R, Banerji S, et al (2002). Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res, 62, 1315-20.
  22. Bluff JE, Menakuru SR, Cross SS, et al (2009). Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer, 101, 666-72.
  23. Boneberg EM, Legler DF, Hoefer MM, et al (2009). Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. Br J Cancer, 101, 605-14.
  24. Bono P, Wasenius VM, Heikkila P, et al (2004). High LYVE-1 positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res, 10, 7144-9.
  25. Dhakal HP, Bassarova A, Naume B, et al (2009). Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count. Histol Histopathol, 24, 1049-59.
  26. Duff SE, Jeziorska M, Kumar S, et al (2007). Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis, 9, 793-800.

Cited by

  1. Prognostic factors in patients with recurrent or metastatic retroperitoneal leiomyosarcoma vol.11, pp.12, 2015,